ID | 114544 |
Author |
Yagi, Shusuke
Tokushima University|Shikoku Central Hospital
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Hirata, Yukina
Tokushima University
Ise, Takayuki
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Kusunose, Kenya
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Yamada, Hirotsugu
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Salim, Hotimah Masdan
Tokushima University
Maimaituxun, Gulinu
Tokushima University
Nishio, Susumu
Tokushima University
Takagawa, Yuriko
Tokushima University
Hama, Saori
Tokushima University
Matsuura, Tomomi
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Yamaguchi, Koji
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Soeki, Takeshi
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Wakatsuki, Tetsuzo
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Aihara, Ken‑ichi
Tokushima University
Akaike, Masashi
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Sata, Masataka
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
|
Keywords | Epicardial adipose tissue
SGLT2 inhibitors
Echocardiography
|
Content Type |
Journal Article
|
Description | Background: It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease.
Methods and results: We administered 100 mg of canagliflozin for 6 months to 13 patients with type 2 diabetes mellitus. We evaluated glycemic control, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area, and skeletal muscle mass by using impedance methods, and EAT thickness by using echocardiography. Canagliflozin treatment for 6 months decreased hemoglobin A1c level from 7.1 ± 0.5% to 6.7 ± 0.6% (P < 0.05) and decreased EAT thickness from 9.3 ± 2.5 to 7.3 ± 2.0 mm (P < 0.001), along with a trend of decreasing VAT and SAT area. No association was found between any of these changes. Conclusion: Canagliflozin reduced EAT thickness in patients with type 2 diabetes mellitus independent of its effect on lowering blood glucose, suggesting that canagliflozin may have an effect in preventing cardiovascular events in these patients (UMIN000021327). |
Journal Title |
Diabetology & Metabolic Syndrome
|
ISSN | 17585996
|
Publisher | BioMed Central|Springer Nature
|
Volume | 9
|
Start Page | 78
|
Published Date | 2017-10-04
|
Rights | © The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
|
EDB ID | |
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
Medical Sciences
University Hospital
|